Therapy Finder Advisor

Heinz-Josef Lenz, M.D.
Professor of Medicine,
Associate Director Clinical Research USC/Norris Comprehensive Cancer Center
Kathryn Balakrishnan Chair for Cancer Research,
Co-Chair of the GI Oncology Program, and Co-Director USC Center for Molecular Pathways and Drug Discovery

Learn the Science Behind This Tool

Science and the Colorectal Molecular Disease Model

Drugs in the News for Colorectal Treatment

The treatment of advanced colorectal cancer has greatly benefited by approval of targeted therapies in the past few years. Avastin and Erbitux are targeted therapies that are a part of the standard of care for colorectal cancer patients. Newer targeted therapies, such as Regorafenib, are in clinical trials for colorectal cancer and promise to benefit even more colorectal cancer patients. These advances are also driving personalization of treatments for colorectal cancer patients based on their tumors’ molecular fingerprint.

Drug	Other names	Target	Manufacturer	Status
Nexavar	BAY 43-9006, Sorafenib	VEGF/R, RAF, PDGFR	Bayer	In phase 2 trials for colorectal cancer and phase 3 trials for a variety of other cancers, including breast and pancreatic. Nexavar is FDA approved to treat liver cancer and renal cell carcinoma.
Regorafenib	BAY 73-4506	VEGFR, RAF, PDGFR, Kit, Ret	Bayer	In phase 3 trials for colorectal cancer.

This list features only some of the drugs discussed in the Targeted Therapy Finder. Find drugs that may be relevant to you by providing information about your colorectal on the home page.